Ongoing Treatment Challenges in Chronic Lymphocytic Leukemia (CLL)

Overview

• Objectives:
1. Highlight the ongoing treatment challenges faced by patients with CLL.
2. Increase awareness of unmet needs across the CLL treatment journey.
3. Discuss considerations for treatment sequencing and management in relapsed/refractory CLL.

Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]

24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

For Lilly product information: email: [email protected]

For further information, please contact:

Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

CMAT-17532